Isracann Biosciences Inc. announce that further to its acquisition of Praesidio Health Inc. as a natural health medicine division, the Company has elected to expand its leadership team effective immediately. Mr. James (JT) Thompson joins as Chief Operations Officer:- Mr. Thompson is recognized as an established industry leader, dedicated to building high-performance teams and cultures. He brings extensive experience in strategic development and go-to-market execution, having previously dementated increased return on investment in operations and finance.

Mr. Matt Chatterton moves to Chief Science Officer The appointment of a new COO allows Mr. Chatterton to focus his efforts and expertise on the engagement and support of clinical studies, as well as oversee manufacturing processes including qualification and management of suppliers and vendors. He will also serve as principle contact and regulatory lead with the FDA & Health Canada and ensure good governance of patient surveys regarding initial efficacy studies with the Praesidio division health practitioners, including senior doctors and specialists. The Company further advises that Mr. Darryl Jones has resigned from the board of directors and the Company.